New Bispecific Drug Cuts Lung Cancer Death Risk by 34% in Major Trial
Ivonescimab, combining two proven cancer therapies, significantly extended survival in squamous non-small cell lung cancer patients.
Summary
Ivonescimab, a drug that merges the mechanisms of two blockbuster cancer medicines, reduced the risk of death by 34% compared to standard treatment in patients with squamous non-small cell lung cancer. The results come from a large clinical trial conducted in China by Akeso Therapeutics and were presented at the American Society of Clinical Oncology annual meeting, with simultaneous publication in The Lancet. The drug is being developed outside China by Summit Therapeutics. Oncologists say the outcome exceeded expectations. While promising, the trial's China-only design raises questions about generalizability to broader global populations, and debate is expected around the data's applicability to Western clinical practice.
Detailed Summary
Ivonescimab is a bispecific antibody — a drug engineered to block two cancer-driving pathways simultaneously — that combines the activity of a PD-1 immune checkpoint inhibitor and an anti-VEGF agent, two of the best-selling classes of cancer drugs in the world. Its developer, Akeso Therapeutics, has now reported a significant clinical milestone in lung cancer treatment.
In a clinical trial conducted entirely in China, ivonescimab reduced the risk of death by 34% compared to a standard treatment in patients with squamous non-small cell lung cancer (NSCLC). The findings were presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago and published simultaneously in The Lancet, lending the results immediate scientific visibility and credibility.
Oncologists attending the conference described the outcome as exceeding expectations. Squamous NSCLC is a subtype of lung cancer historically associated with limited therapeutic options and poorer responses to immunotherapy alone, making a 34% reduction in mortality risk a clinically meaningful advance if the results hold up in broader populations.
Summit Therapeutics, which holds the rights to develop ivonescimab outside of China, characterized the data as evidence of a highly valuable pipeline asset. The drug's dual mechanism could represent a new standard-of-care approach if regulatory bodies in the US and Europe accept the China-derived data or require additional confirmatory trials.
However, important caveats apply. The trial was conducted exclusively in China, and differences in patient genetics, comorbidities, prior treatments, and healthcare standards may limit direct extrapolation to Western populations. Regulatory agencies like the FDA often scrutinize single-region trials. Additionally, the full article is behind a paywall, restricting independent review of trial design, dosing, adverse events, and statistical methodology — all critical factors for assessing true clinical impact.
Key Findings
- Ivonescimab reduced death risk by 34% vs. standard treatment in squamous non-small cell lung cancer patients.
- The drug combines PD-1 checkpoint inhibition and anti-VEGF activity in a single bispecific antibody.
- Results were published in The Lancet and presented at ASCO 2026, indicating high-level scientific scrutiny.
- Trial was conducted entirely in China, raising questions about generalizability to Western populations.
- Summit Therapeutics is developing ivonescimab outside China, with potential global regulatory submissions ahead.
Methodology
This is a news report from STAT News summarizing clinical trial data presented at ASCO 2026 and published in The Lancet. The source is credible and specialized in biomedical reporting. The full trial data are paywalled, limiting independent verification of methodology, endpoints, and safety profiles.
Study Limitations
The trial was conducted exclusively in China, which may limit applicability to genetically and clinically diverse Western populations. The full article is behind a paywall, preventing complete assessment of trial design, adverse events, and statistical methods. Regulatory acceptance by the FDA or EMA will require further scrutiny or additional confirmatory studies.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.